GnRHa Trigger in Asian Oocyte Donors- a Dose Finding Study

NCT02208986 ↗

Completed 165 enrolled Vietnam National University Aarhus University Hospital · collab Merck Sharp & Dohme LLC · collab The Fertility Clinic, Skive Regional Hospital, Denmark · collab University of Southern Denmark · collab

RandomizedParallel-groupOpen-labelTreatment

Summary

The aim of this randomized single center study is to explore the most optimal dose of GnRHa used for triggering of final oocyte maturation in IVF. The study group will consist of oocyte donors who have GnRHa trigger as a standard trigger concept. Hypothesis: In an Asian oocyte donor population, the use of 0.2 mg, 0.3mg or 0.4 mg of GnRHa will lead to the retrieval of comparable numbers of mature oocytes (MII) and good quality embryos. Moreover, the reproductive outcome in the recipients will be similar regardless of the dose of GnRHa used for trigger.

Timeline

Start: 2014-08
Primary completion: 2015-02
Completion: 2015-03

Publications

Vuong TN, Ho MT, Ha TD, Phung HT, Huynh GB, Humaidan P. Gonadotropin-releasing hormone agonist trigger in oocyte donors co-treated with a gonadotropin-releasing hormone antagonist: a dose-finding study. Fertil Steril. 2016 Feb;105(2):356-63. doi: 10.1016/j.fertnstert.2015.10.014. Epub 2015 Oct 31.

Drugs

Evaluation	Drug	Modality	Dose	Route
Comparator	Triptorelin	Other / unclassified	0.2 mg	Subcutaneous
Comparator	Triptorelin	Other / unclassified	0.3 mg	Subcutaneous
Comparator	Triptorelin	Other / unclassified	0.4 mg	Subcutaneous

Indications

No indication recorded.